Advanced Breast Cancer
228
65
83
66
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
33 trials with published results (14%)
Research Maturity
66 completed trials (29% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.5%
17 terminated out of 228 trials
79.5%
-7.0% vs benchmark
12%
27 trials in Phase 3/4
50%
33 of 66 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 66 completed trials
Clinical Trials (228)
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.